The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

ScinoPharm Taiwan pointed out that since its approval in 1996, glatiramer acetate has been recognized as one of the most ...

Disease-Modifying Therapy Comparison and Side Effects ...

The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...

Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...

The FDA approved the first generic version of Copaxone (glatiramer acetate injection) to treat patients with relapsing forms of multiple sclerosis (MS), giving a green light to the abbreviated new ...

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.S. FDA has approved its Glatiramer Acetate Injection, a generic version of Teva's Copaxone, for the treatment of adult patients ...